Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The study is a phase II clinical trial of single arm. The purpose is to evaluate the safety
and efficacy of anti-PD-1 antibody Toripalimab combined with
chemotherapy(gemcitabine+5-fluorine pyrimidine) in unresectable advanced cholangiocarcinoma
patients.